# Psychiatric Pharmacotherapy Update

## Day I: Live Online Broadcast • Thursday, October 21, 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Summary</th>
</tr>
</thead>
</table>
| 8:30 am | Psychotropic New Drug Update                                             | Stephen R. Saklad, Pharm.D., BCPP  
Director, Psychiatric Pharmacy  
Clinical Professor  
The University of Texas at Austin College of Pharmacy | • Describe the pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs recently marketed as well as drugs approaching the market.  
• Review pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs that have been released in the past five years. |
| 15 min | Break                                                                   |                                                                            |                                                                         |
| 9:45   | Reducing Suicide Among Youth, Their Families and Communities with the Columbia Protocol | Kelly Posner Gerstenhaber, PhD  
Professor, Columbia University  
Founder and Director, The Columbia Lighthouse Project  
Recipient, Secretary of Defense Medal for Exceptional Public Service  
Columbia University/New York State Psychiatric Institute | • Discuss how preventative suicide screening models can be used to identify at-risk individuals and establish care plans that reduce suicide while allocating resources effectively.  
• Utilize a systemic best-practice measurement, the C-SSRS, to identify suicidal ideation and behavior to improve risk identification and safety monitoring, which ultimately aids prevention.  
• Demonstrate how the C-SSRS enables more streamlined triage, provides liability protection and facilitates care delivery to those at highest risk.  
• Identify steps taken to implement a comprehensive screening program within an agency. |
| 15 min | Break                                                                   |                                                                            |                                                                         |
| 11:00  | Update on Childhood Aggression                                          | Joseph Blader, PhD  
Meadows Foundation & Semp Russ Professor of Child Psychiatry  
Departments of Psychiatry & Behavioral Sciences and Pediatrics  
Joe R. and Teresa Lozano Long School of Medicine  
University of Texas Health Science Center at San Antonio | • Review the psychiatric conditions in which aggressive behaviors arise in youth.  
• Discuss sociocultural and regulatory factors that impact clinical care and the evidence base for pharmacotherapy.  
• Discuss current non-pharmacological and pharmacological strategies for treatment of aggression among children with psychiatric disorders.  
• Discuss adverse effect liabilities of pharmacotherapies often used for aggressive behavior.  
• Review the limit evidence base for combined medication approaches, and impact of rigorous implementation of first-line treatments.  |
| Noon   | Lunch Break                                                             |                                                                            |                                                                         |
| 1:00 pm| Treatment of Psychiatric Symptoms in Neurocognitive Disorders          | Jason Schillerstrom, M.D.  
Professor, Department of Psychiatry  
The University of Texas Health Science Center San Antonio | • Review new and emerging therapies as well as risks associated with current pharmacotherapies.  
• Evaluate evidence and risk vs. benefit of medication treatment as well as any nonmedication modalities.  
• Review current blackbox warnings and potential ethical issues related to patient communication. |
| 15 min | Break                                                                   |                                                                            |                                                                         |
| 2:15   | Appropriate Use of Complementary and Alternative Medical CAM for Psychiatric Disorders | Marisa S. P. Toups, M.D.  
Owner / Psychiatrist  
Singularity Psychiatry and Mental Health  
Affiliate Assistant Professor  
UT Southwestern Medical School Department of Psychiatry | • Discuss often used complementary and alternative medicines (CAM) often used in psychiatric treatments.  
• Review evidence to evaluate agents that may be beneficial vs no benefit.  
• Discuss potential ethical issues related to use of CAM in psychiatric treatments. |
| 15 min | Break                                                                   |                                                                            |                                                                         |
| 3:30   | Managing Dual Diagnosis: Substance Use and Psychiatric Disorders       | Amanda Simonton, PhD, APRN, PMHNP-BC  
Clinical Assistant Professor  
The University of Texas at Austin School of Nursing | • Discuss the context of dual-diagnosis and diagnostic considerations.  
• Recall medication considerations and treatment caveats associated with dual-diagnosed disorders.  
• Implement trauma-informed care principles into practice. |
### Medication Treatment of Co-Occurring Opioid and Alcohol Use Disorders
*Lucas Hill, Pharm.D., BCPS, BCACP*
Clinical Associate Professor
The University of Texas at Austin College of Pharmacy

- Describe recent trends in use and harms of opioids and alcohol
- Summarize current evidence and key ethical issues related to medication treatment of co-occurring opioid and alcohol use disorders
- Develop a medication treatment plan for a patient with co-occurring opioid and alcohol use disorders that integrates patient-specific factors relevant to psychiatric clinicians

### Schizophrenia Update: 2021
*Troy A. Moore, Pharm.D., M.S, BCPP*
PGY1 Residency Program Director
Clinical Pharmacy Specialist, Mental Health
VA Eastern Colorado Health Care System

- Assess the impact of co-occurring disorders on schizophrenia
- Discriminate between the new potential drug targets in schizophrenia and how they may impact the treatment of schizophrenia
- Evaluate some of the new literature examining medication treatment in schizophrenia and how it will impact outcomes

### Treating Behavioral Manifestations of Traumatic Brain Injury
*M. Rais Baig, M.D.*
Research Instructor of Psychiatry & Behavioral Sciences
Department of Psychiatry UT Health Science Center San Antonio

- Describe the classification of Traumatic Brain Injury (TBI).
- Describe behavioral manifestations of TBI.
- Discuss the management of individuals with TBI.

### Use of Psychotropic Serum Concentrations in Clinical Practice
*Stephen R. Saklad, Pharm.D., BCPP*
Director, Psychiatric Pharmacy
Clinical Professor
The University of Texas at Austin College of Pharmacy

- Review of which medications can have meaningful levels drawn
- Discuss how to use meaningful levels in clinical practice
- Discuss subtherapeutic levels / toxic levels
- Include genetics topic / ethics topic and testing of genetics testing

### Eating Disorder Update
*Sean Kerrigan, M.D.*
Psychiatrist
UT Health Austin Pediatric Psychiatry at Dell Children’s

*Hani Talebi, Ph.D., LSSP*
Vice President, Health Systems Integration
Meadows Mental Health Policy Institute
Affiliate Faculty, Dept of Psychiatry and Behavioral Sciences
The University of Texas at Austin Dell Medical School

- Discuss evidence-based treatments for eating disorders
- Discuss Vyvanse use for binge eating disorder
- Discuss role of psychotherapy and other approaches in the treatment of eating disorders

### Evaluating the Evidence for Teratogenicity of Psychotropic Medications
*Jeffrey Newport, M.D.*
Director of Women’s Reproductive Mental Health
UT Health Austin

- Review evidence-based data regarding potential teratogenicity of psychotropic medications
- Discuss best practices regarding use of psychotropic medications during and after pregnancy
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
<th>Description</th>
</tr>
</thead>
</table>
| 1.00 On Demand | New Agents for Mental Health and Neurologic Disorders | Stephen R. Salkalad, Pharm.D., BCPP  
Director, Psychiatric Pharmacy  
Clinical Professor  
The University of Texas at Austin College of Pharmacy | - Describe the efficacy and safety data of the emerging and recently approved psychiatric and neurologic medication pipeline.  
- Discuss appropriate monitoring requirements, patient education points, and provider education for these agents.  
- Discuss clinical use of new and emerging medications |
| 1.00 On Demand | The Management of Behavioral and Psychological Symptoms of Dementia (BPSD) in the Era of Boxed Warnings | Rajesh R. Tampi, M.D., M.S., D.F.A.P.A  
Professor of Psychiatry  
Case Western Reserve University School of Medicine  
Associate Clinical Professor of Psychiatry, Yale School of Medicine  
President Elect, American Association for Geriatric Psychiatry | - Describe the epidemiology of BPSD  
- Elucidate the neurobiology and assessment of individuals with BPSD.  
- Discuss the management of individuals with BPSD.  
- Discuss recent controversies in the treatment of individuals BPSD. |
| 1.00 On Demand | Treatment of Agitation and Impulsivity in Youth with Autism Spectrum Disorder | Eric Shute, M.D  
Psychiatrist, UT Health Austin Pediatric Psychiatry  
Dell Children’s Medical Center  
Mariel Cannady, PsyD  
Psychologist, UT Health Austin Pediatric Psychiatry  
Dell Children’s Hospital | - Describe agitation and impulsivity as features of emotion dysregulation common in ASD  
- Introduce evidence-based behavioral strategies for management of emotion dysregulation in youth with ASD  
- Introduce evidence-based pharmacological strategies for management of emotion dysregulation, impulsivity and aggression/agitation in autistic youth  
- Describe the evidence base for, and importance of, a multidisciplinary approach to managing the externalized symptoms of neurodiverse youth. |
| 1.00 On Demand | Overcoming Barriers to Clozapine | Deanna L. Kelly, Pharm.D., BCPP  
Professor of Psychiatry  
Director, Treatment Research Program (TRP)  
Maryland Psychiatric Research Center (MPRC)  
University of Maryland School of Medicine | - Discuss the utility of clozapine in the treatment resistant schizophrenia  
- List significant barriers to the use of clozapine  
- Recognize new data and strategies to overcome some barriers to clozapine use including point of care monitoring, new plasma level assay, and emerging data in patients with Benign Ethnic Neutropenia |
| 1.00 On Demand | Tardive Dyskinesia Update | Steven Stoner, Pharm.D., BCPP  
Chair and Clinical Professor  
Division of Pharmacy Practice and Administration  
University of Missouri Kansas City School of Pharmacy | - Review 2020 American Psychiatric Association Guidelines for the treatment of patients with schizophrenia who develop tardive dyskinesia.  
- Critique short and long-term treatment considerations for managing tardive dyskinesia and discuss the role of VMAT2 inhibitors in the treatment continuum of tardive dyskinesia.  
- Explore the detrimental impact of tardive dyskinesia on global functionality and demonstrate how VMAT2 inhibitors can improve functionality and overall quality of life (e.g., improved mobility, self-care, social activities, and life responsibilities). |
| 1.00 On Demand | Analysis of Drug Diversion | Diane B. Ginsburg, Ph.D., M.S., R.Ph., FASHP  
Clinical Professor, Pharmacy Practice Division  
Associate Dean for Healthcare Partnerships  
G.D. Searle Endowed Fellow in Pharmacy  
The University of Texas at Austin College of Pharmacy | - Describe drugs involved in diversion and the impact on the opioid crisis  
- Discuss how to identify potential prescribing and diversion red flags and action steps regarding suspicious activities |
| 1.00 On Demand | Acute Pain Management with Patients with OUD | Kirsten Mason, PharmD, BCPS  
Regional Clinical Pharmacy Manager  
Ascension Texas | - Develop an approach to manage pain with hospitalized individuals with opioid use disorder (OUD)  
- Compare pain management strategies for individuals with OUD taking buprenorphine, methadone, extended release naltrexone, and non-prescribed opioids  
- Review transitions of care considerations for patients with OUD |
| 1.00 On Demand | Role of Stigma in Opioid Use Disorder | Richard Bottner, PA-C  
Assistant Professor, Department of Internal Medicine  
The University of Texas at Austin Dell Medical School | - Define stigma and its historical origins  
- Identify different types of stigma  
- Discuss how stigma decreased access to care for people with substance use disorders |